Related Experiment Videos
Biological evaluation of Mycoplasma pulmonis temperature-sensitive mutants for use as possible rodent vaccines
1Division of Comparative Medicine, University of Texas Southwestern Medical Center, Dallas 75235.
Abstract:
Temperature-sensitive mutants (TSMs) of Mycoplasma pulmonis were produced by treating the wild-type strain with N-methyl-N'-nitro-N-nitrosoguanidine. Three TSMs were selected at 38 degrees C, as a restrictive temperature, and at 34 degrees C, as a permissive temperature. Two TSMs, UTCMI and UTCMII, were proven to be nonpathogenic but immunogenic. In addition, they did not induce pneumonia, tracheitis, or tympanitis but did induce mild rhinitis. They were stable after 10 passages in vitro and in vivo. They elicited excellent antibody production and cell-mediated immunity in vaccinated rats. They also were not mitogenic to rat lymphocytes. Rats immunized intranasally with these TSMs were significantly protected against challenge with wild-type organisms. These mutants were morphologically and serologically indistinguishable from the wild-type organisms. The growth characteristics and antibiotic sensitivities were similar to those of wild-type organisms, except that they grew only at 34 degrees C. In contrast to wild-type organisms, they did not bind to or lyse sheep erythrocytes. Thus, these TSMs may qualify as a vaccine to prevent M. pulmonis infection in rats.
Insights
New temperature-sensitive mutants (TSMs) of Mycoplasma pulmonis are nonpathogenic yet immunogenic. These TSMs show promise as a safe and effective vaccine candidate for preventing Mycoplasma pulmonis infections in rats.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Mycoplasma pulmonis is a common respiratory pathogen in rats.
- Developing safe and effective vaccines against M. pulmonis is crucial for animal health.
- Temperature-sensitive mutants (TSMs) offer a potential avenue for vaccine development due to their conditional replication.
Purpose of the Study:
- To generate and characterize temperature-sensitive mutants (TSMs) of Mycoplasma pulmonis.
- To evaluate the safety, immunogenicity, and protective efficacy of these TSMs in a rat model.
- To determine the potential of these TSMs as a live vaccine candidate.
Main Methods:
- Wild-type Mycoplasma pulmonis was treated with N-methyl-N'-nitro-N-nitrosoguanidine to create TSMs.
- TSMs were selected based on their growth at permissive (34°C) and restrictive (38°C) temperatures.
- Safety, immunogenicity (antibody and cell-mediated immunity), and protection against wild-type challenge were assessed in rats.
Main Results:
- Two stable, nonpathogenic, yet immunogenic TSMs (UTCMI and UTCMII) were isolated.
- These TSMs induced mild rhinitis but not severe respiratory diseases like pneumonia.
- Intranasal immunization with TSMs conferred significant protection against M. pulmonis challenge in rats.
- TSMs were morphologically and serologically similar to wild-type but grew only at 34°C.
Conclusions:
- The characterized TSMs of Mycoplasma pulmonis are safe and immunogenic.
- These mutants demonstrate potential as a live vaccine for preventing M. pulmonis infections in rats.
- Further studies are warranted to explore their vaccine efficacy in diverse settings.